Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top New White Paper by Cowen Royalty and Health Advances Provides Key Solutions for Long-Term Financial Success
STAMFORD, Conn. and WESTON, Mass., Nov. 6 /PRNewswire/ -- Those biopharmaceutical companies that are able to incorporate innovative and flexible elements into their business models will be best positioned to survive healthcare reform and maintain attractive long-term returns, according to a white paper published today by Cowen Healthcare Royalty Partners, a global healthcare private equity firm, and Health Advances, a leading healthcare strategy firm.
The paper, "Maintaining Attractive Biopharma Returns in the Face of Healthcare Reform", examines key issues at the center of the debate including access to care, controlling costs, drug pricing and value-based healthcare. In addition to discussing the increased pressures biopharma companies face, including the restrictive use of branded drugs for large patient populations and follow-on biologics, the paper outlines new solutions companies can implement to achieve the same levels of return for its investments as it has in the past.
Some of the paper's key findings include:
- Biopharma companies need to adapt their business models to maintain attractive ROIs such as exploring pay-for-performance relationships with stakeholders, cost-effective care solutions that align incentives, and investing in follow-on biologics and/or generics
- Investing in pharmacoeconomic competencies and integrating these into clinical development will mitigate reimbursement risk
- Investing in personalized healthcare and specifically biomarkers will be rewarded
- Highly differentiated products addressing niche markets will be the least vulnerable even if stringent regulation is passed
Gregory B. Brown, M.D., Co-Founder and Managing Director of Cowen Royalty, commented, "Healthcare reform is a serious issue for biopharma companies who are already feeling pressure from patent expirations, fewer drug approvals and growing development costs. We partnered with Health Advances to bring a new and unique perspective on the healthcare debate especially as it relates to biopharma companies -- the developers of many of our future medicines."
To download a copy of the white paper visit http://www.cowenroyalty.com/content/news/publications-presentations.htm.
About Cowen Healthcare Royalty Partners:
Cowen Healthcare Royalty Partners is a global healthcare private equity firm that invests principally in commercial-stage biopharmaceutical and medical device companies and products, through the purchase of royalty interests. The investment team has over 100 years of healthcare related experience including principal investing, structured finance, healthcare industry senior management, Wall Street research and consulting, scientific and clinical experience. For more information, visit www.cowenroyalty.com.
About Health Advances:
Founded in 1992, Health Advances is a leading healthcare strategy firm advising clients in the biopharma, device and diagnostic sectors. Industry executives and investors rely on Health Advances to advise them on their most challenging commercial decisions. For more information regarding our consulting services, visit www.healthadvances.com.
Kellie Walsh 914-315-6072 email@example.com
SOURCE Cowen Healthcare Royalty Partners